BRISBANE: Obstructive Sleep Apnoea (OSA) treatment innovator, Oventus Medical Ltd has signed an agreement with Careica Health, one of western Canada’s largest privately-owned providers of diagnostics and treatment for obstructive sleep apnoea and home oxygen services.
Under the agreement, patients will be referred from Careica’s 26 homecare locations which span the provinces of Manitoba, Saskatchewan, Alberta, and British Columbia to an initial four sites which will operate the Oventus Lab in Lab business model. The agreement extends Careica’s well known SLEEP program which will now include Oventus’ 02Vent oral appliance therapy as an alternative for CPAP-intolerant individuals.
Cory McArthur, Careica’s President and CEO commented, “We are excited about the partnership with Oventus as we believe there is considerable opportunity for not only a Lab in Lab model, but also to extend our SLEEP program to include dental sleep treatment. The precise way in which 02Vent Optima devices fit patients means we expect a very low number of product adjustment requests which should enable smooth and efficient delivery of the product under our telemedicine offering for patients.”
Dr Chris Hart, founder and CEO of Oventus commented, “Careica has been operating a successful respiratory business for more than 20 years. Oventus is proud that such a well-respected Canadian sleep group has chosen to augment their existing sleep offering by adopting our treatment platform. As COVID-19 restrictions start to lift in Canada, we currently expect to see the four Lab in Lab sites deployed by mid June.”
Once fully deployed, each location expects to order a minimum of 20 02Vent Optima devices per month. The agreement has a term of three years, with an automatic three year renewal, unless a party elects not to renew no later than 180 days prior to the end of the three year period.